SCHEMBL23217364

SCHEMBL23217364

COc1ccc(Cl)c(Cl)c1[C@H]1C[C@@H](C(C)=O)N(C(=O)O)C1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 8/20 0.43
HTR2A P28223 7/20 0.43
HTR2B P41595 7/20 0.43
FFAR2 O15552 1/20 0.34
DRD2 P14416 1/20 0.33
MTNR1B P49286 1/20 0.33
CLCN2 P51788 1/20 0.33
MMP2 P08253 1/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
GRIN2B Q13224 1/20 0.32
KDM4E B2RXH2 1/20 0.32
TP53 P04637 1/20 0.32
PKM P14618 1/20 0.32
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23217172 0.91 HTR2C (0.44) HTR2CHTR2AHTR2BFFAR2DRD2
SCHEMBL23217480 0.91 HTR2C (0.44) HTR2CHTR2AHTR2BFFAR2DRD2
SCHEMBL23217322 0.91 HTR2C (0.41) HTR2CHTR2AHTR2BFFAR2DRD2
SCHEMBL23217113 0.91 HTR2C (0.41) HTR2CHTR2AHTR2BFFAR2DRD2
SCHEMBL23227414 0.85 HTR2A (0.42) HTR2CHTR2AHTR2BPDE4B
SCHEMBL23217410 0.85 HTR2C (0.39) HTR2CHTR2AHTR2BDRD2MTNR1B
SCHEMBL23217318 0.82 HTR2C (0.41) HTR2CHTR2AHTR2BDRD2CLCN2
SCHEMBL23217435 0.82 HTR2C (0.45) HTR2CHTR2AHTR2BFFAR2DRD2
SCHEMBL23217149 0.82 HTR2C (0.45) HTR2CHTR2AHTR2BDRD2CLCN2
SCHEMBL23217560 0.82 HTR2A (0.42) HTR2CHTR2AHTR2BFFAR2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-02-16 US disclosed
EP-4041405-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. Shaw Research, LLC (US) 2022-08-17 EP disclosed
CN-114828963-A Arylheterobicyclic compounds as Kv1.3 potassium SHAKER channel blockers D·E·萧尔研究有限责任公司 2022-07-29 CN disclosed
WO-2021071832-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNB1, KCNJ2, KCNB2 HTR2C 1162/4885HTR2A 1799/4885HTR2B 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.